
åã©ããã¡ãå®ãããã«ã倧人ã¯ã©ãããã¹ããïŒ
ãåã©ããžã®ã¯ã¯ãã³æ¥çš®ãšã¯ã¯ãã³åŸéºçãèããè¶ å æŽŸè°å¡é£çãäž»å¬ã§10æ18æ¥ã«éå¬ãããããå°éå®¶ã亀ããã¯ã¯ãã³å€§è°è«äŒãã¯çŸåšãã¢ãŒã«ã€ãé ä¿¡ã§èŠãããŸãããã¬ãã§ã¯åãäžããããŠããŸãããåã©ããžã®ã³ããã¯ã¯ãã³æ¥çš®ãæ€èšããäžã§ãšãŠãéèŠãªããšãèªãããŸããã
å°éå®¶ã亀ããã¯ã¯ãã³å€§è°è«äŒ
çŽ90åã®åç»ã§ãããåã©ããã¡ãžã®æ¥çš®ã«ã€ããŠèããããã®ãéèŠãªæ å ±ãããããå«ãŸããŠããŸãã
åœæ¥ã¯ã4人ã®å°éå®¶ãåå ãããããããã®ç«å Žã§ã¯ã¯ãã³ã«ã€ããŠèª¬æãããŸããã
1çªç®ïŒæäžåº·ææ°ã(æ±äº¬çç§å€§åèªææãå
ç«å»åŠãæäœç ç©¶)
2çªç®ïŒæ£®å
浩幞æ°ã(é·åŽå€§åŠç
é¢ å°å
ç§ ææãæ¥æ¬å°å
ç§åŠäŒå°éå»ãããããããããããã¬ãçªçµã«ã倿°åºæŒ)
3çªç®ïŒäºäžæ£åº·æ°ã(倧éªåžç«å€§åŠåèªææãååç
æ
åŠ)
4çªç®ïŒå°å³¶å¢ãæ°ã(åå€å±å€§åŠåèªææãå°å
ãã)
1ã€æ°ã«ãªã£ãã®ãè°å¡ããã®è³ªåã§ãæäžæ°ããBA.4/BA.5察å¿ã¯ã¯ãã³ã¯ããã§ã®è©Šéšãå šãè¡ã£ãŠããªãããšçããéšåãæ¿èªç³è«æã«ã¯ããŸã ããã§ã®ããŒã¿ãåºãŠããŸããã§ããããèšåºè©Šéšã¯8æããè¡ãããŠããŸãããããŠå æ¥ãæäž7æ¥åŸã®ããŒã¿ãåŸããããšçºè¡šãããŸããïŒäžèšåç §ïŒã80人ãšããå°ãªã人æ°ã§ãããŒãã§ã¯ãªãã®ã§ããå šãè¡ã£ãŠããªãããšã¯èšããªããšæããŸãã
çµå±ãåã©ããžã®æ¥çš®ã«ãããã£ããã¯ããã®ãïŒ
ä»ååå ãã4人ã®å°éå®¶ã®äžã§ãæ£®å æ°ãæšé²æŽŸãšããŠåå ããããšæããŸãããæ£®å æ°ã®æ¬å¿ã¯ãæšé²æŽŸãã§ã¯ãªãããã«æããŸããã
以äžãæ£®å æ°ã®è³æïŒäžéšïŒã§ãã


ã³ãããããã€ã³ãã«ãšã³ã¶ãRSãŠã€ã«ã¹ææçã®æ¹ãé倧ãªåé¡ã§ãããæ¥æ¬ã®åã©ãã«ãšã£ãŠã³ããã¯ãã¢ã¡ãªã«ã®åã©ãã»ã©ã€ã³ãã¯ãããªããšèªã£ãŠããŸãã
ãã ãããªãã¯ãã³æ ªã«ãªã£ãŠãããéçåã«ããæ¥æ§è³çã®çºçãå¢ããŠããããšãèšã£ãŠããŸããã
ã5æ³ãã11æ³çšã¯ã¯ãã³ã®ãªãã¯ãã³æ ªã«å¯Ÿããææäºé²å¹æã¯31ïŒ ã ããçºçäºé²å¹æã¯48ïŒ ãå ¥é¢ãé²ã广ã¯çŽ83ïŒ ããããããã¯ã¯ãã³ã¯ååã«æå¹ã ãšèª¬æããŸããã



以äžãç§ã®çåã§ãã
éçåãäºé²ãã广ããããšããŠããå¹æã®æç¶ã«ã€ããŠã¯ç¢ºç«ãããŠããŸããïŒäžèšãµã€ãããæ·»ä»ææžåç
§ïŒãããã«ã€ããŠã¯ãã©ãèããŠããã®ã§ããããã

å¯åå¿ã«ã€ããŠã¯ã蚱容ã§ããç¯å²ããšã®ããšã§ãã5æ³ãã11æ³ã®å¿ççã«ã€ããŠã¯ããããã軜çã§èªç¶ã«æ²»ãããšèšã£ãŠããŸããããæ¬åœã«ããã§ããããã
ååŽçãå ¬éããŠããå¯åå¿çãã®å ±åã«ã¯ãå ±åå»åž«ããäºè±¡ãçåœãè ããããšåé¡ãããããä»åŸããŒã¹ã¡ãŒã«ãŒãå¿ èŠãšããå¯èœæ§ãããããšæžããŠããå¿ççã®å ±åããããŸãïŒäžèšåç §ïŒããããã軜çãšãããã®ã§ããããã
ãã³ããææã«ããæ¥æ§è³çãçºçããäºäŸãå¢ããŠããããšããä»¶ã«ã€ããŠã¯ãã¯ã¯ãã³æ¥çš®åŸã®æ¥æ§è³çãæµ·å€ããå ±åãããŠããã®ã§ãããããã«ã€ããŠã¯ã©ã®ããã«èããŠããã®ã§ããããã
ã¯ã¯ãã³æ¥çš®åŸã®æ¥æ§è³çã«é¢é£ããäºäŸã«ã€ããŠã¯ãäžèšã®èšäºã§åãäžããŸããã
以äžãäžéšãæžãåºããŸãã
ååŽçãµã€ããããŒã > æ¿çã«ã€ããŠ> 審è°äŒã»ç ç©¶äŒç> åçç§åŠå¯©è°äŒ(äºé²æ¥çš®ã»ã¯ã¯ãã³åç§äŒ å¯åå¿æ€èšéšäŒ)> 第85ååçç§åŠå¯©è°äŒäºé²æ¥çš®ã»ã¯ã¯ãã³åç§äŒå¯åå¿æ€èšéšäŒã什åïŒå¹ŽåºŠç¬¬14åè¬äºã»é£åè¡ç審è°äŒè¬äºåç§äŒå»è¬åçå®å šå¯ŸçéšäŒå®å šå¯Ÿç調æ»äŒïŒååéå¬ïŒ10æ7æ¥è³æ
è³æïŒïŒïŒïŒïŒ æ°åã³ããã¯ã¯ãã³æ¥çš®åŸã®æ»äº¡ãšããŠå ±åãããäºäŸã®æŠèŠïŒã³ãããã£ç泚5ïœ11æ³çšïŒãïŒå š6ããŒãžïŒ
äºäŸïŒ2ã11æ³ç·æ§ãã³ãããã£ç泚3åç®æ¥çš®ããããçªå·ïŒFR4267
æ¬ã¯ã¯ãã³äžã®SARS-CoV-2 mRNAã¯é«æ¶²äžã«ç§»è¡ããªããããããŸã§ã«æµ·å€ããæ¬ã¯ã¯ãã³æ¥çš®åŸã®æ¥æ§è³çã®å ±åããããŠããã
æ°åã³ãããŠã€ã«ã¹ã¯ã¯ãã³ãçŽ°èæ§å ç«ã掻æ§åããhyperactive encephalopathyãçºçãããå¯èœæ§ã¯æ®ãããŠããããçŸæç¹ã§ã¯æ¥æ§è³çãæ°åã³ãããŠã€ã«ã¹ã¯ã¯ãã³ã®æ¥çš®ã«ãããšã®æçµçãªçµè«ã¯åºãããŠããªãã
æ¥æ§è³ççºçæ©æã®é«æ¶²ãè¡æž äžã®åçš®ãµã€ãã«ã€ã³æ¿åºŠäžæã®æèŠããããšãå ç«è³ŠæŽ»åãçºçããŠããå蚌ãšãªããhyperactive encephalopathyãçºçããå¯èœæ§ã¯é«ããªãããçŸæç¹ã§ãããã®æèŠã®æ å ±ããªã倿ã§ããªãã
çŸæç¹ã§ã¯æ¥æ§è³çãæ°åã³ãããŠã€ã«ã¹ã¯ã¯ãã³ã®æ¥çš®ã«ãããšã®æçµçãªçµè«ã¯åºãããŠããŸããããããããŸã§ã«æµ·å€ããæ¬ã¯ã¯ãã³æ¥çš®åŸã®æ¥æ§è³çã®å ±åããããŠããããšæžãããŠããŸãã
æ¥æ§è³çã«ãªããªãããã«ã¯ã¯ãã³ãæ¥çš®ããããšããŠããã¯ã¯ãã³æ¥çš®ã«ããæ¥æ§è³çã«ãªãå¯èœæ§ããããªããå¿ççãªã©ã®å¯åå¿ãå«ããŠèããããæ¥çš®ããæ¹ããªã¹ã¯ãé«ããªãã®ã§ã¯ãªãã§ããããã
ããã«æ£®å æ°ã¯ããåºç€çŸæ£ã®ããåã«ãã£ãããšæ¥çš®ããããšã倧åãã ãšèšã£ãŠããŸãããã6ã¶æãã4æ³çšã®ã¯ã¯ãã³ã¯ãæµ·å€ã§ã®å¥åº·å°å ã察象ãšããèšåºè©Šéšã2021幎3æããå§ãŸãããŸã ç¶ç¶äžãåºç€çŸæ£ã®ããå°å ã®ããŒã¿ã¯ããŸã ãªããšæããŸãã
5æ³ãã11æ³ã®æ»äº¡äºäŸã§ã¯ã1äŸç®ïŒ11æ³ïŒã¯åžžã«äººå·¥åŒåžç®¡çã2äŸç®ã¯åæ¯æ§çç¶ã§è¬ãæçšããŠããåã§ãããåºç€çŸæ£ã®ããåã«å¯Ÿããæ¥çš®ã®å®å šæ§ã«ã€ããŠã¯ãã©ã®ããã«èããŠããã®ã§ããããã
æ£®å æ°ã¯ãæ¥çš®ãã¹ã®å¯èœæ§ã«ã€ããŠãè§ŠããŠããŸããããã¹ã®å¯èœæ§ã«ã€ããŠã¯ã以åã®èšäºã§åãäžããŠããŸãïŒäžèšåç §ïŒã

æ£®å æ°ãæã匷調ããŠããããšã¯ããå©ããã¯ãã®åœã倱ãããªãããã«ã¯ãéåžžã®èšºçãè¡ããç°å¢ãæŽããããšãã ã£ããšæããŸãã
倧人ãåã©ããã¡ã®ããã«ããã¹ãããšã¯ãå¿ççãªã©ã®ãªã¹ã¯ããããå¹æã®æç¶æéã確ç«ãããŠããªãã¯ã¯ãã³ãæ¥çš®ãããããšã§ã¯ãªããéåžžã®èšºçãè¡ããç°å¢ãæŽããããšã§ã¯ãªãã®ã§ããããã
çµå±ãæ£®å æ°ã¯ããæ¥çš®ã®æšå¥šã¯åŠ¥åœã ãšèããŠããããåªå矩åãšããèšèã䜿ãããšã«ã¯å察ããšããããšã§ããã
ãåªå矩åããšããããšçŸ©åã®ããã«æãããŸããã矩åã§ã¯ãããŸããïŒãæ¥çš®ãããã¯ãæ¬äººãä¿è·è ãæ±ºããŠããã®ã§ãïŒïŒ